home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Designing and Implementing the Quality System for Combination Products - Webinar By GlobalCompliancePanel

 
  December 01, 2010  
     
 
GlobalCompliancePanel, Online Training Webinar
2011-02-03


Overview: The FDA generally defines combination products as a product composed of any combination of a drug and a device; a biological product and a device; a drug and a biological product; or a drug, device, and a biological product.

Although there are differences between these quality systems, the quality principles embodied in the systems are the same. This course looks at these principles and the processes associated with each principal to design, implement, and maintain a combination system that surpasses compliance requirements. The seminar will focus primarily on the principles embodied in CFR Parts 210-211 and ICH Q7A for pharmaceuticals and Part 820 for medical devices as well as pertinent passages of the International Conference on Harmonization (ICH) and the Global Harmonization Task Force (GHTF) guidances.

The attendees will quickly learn and understand the quality systems principles through the many graphical visual techniques used in the seminar. A quality systems approach will be shown that simplifies and reduces the burden of compliance. You might even want to revamp your quality system after participation in the course.

The presenter will also discuss his many experiences designing and implementing quality systems.

Why Should You Attend: Many quality professionals fear the FDA because they perceive the regulations to be very structured and at the same time open for interpretation. They further perceive the FDA as being the experts interpreting the regulations. It is true that the FDA establishes policy for enforcement of the regulations. It should be remembered the regulations came from industry and furthermore, that the regulations are the minimum requirements. When the pharmaceutical GMP's were issued, it was frequently stated that the regulations would result in only a mediocre or average quality system. This is because more emphasis would be placed on meeting the demand of the regulation, than studying the objective of why the regulation existed.

The FDA has their role and certainly must be respected. But they do not have the experience of implementing and managing quality systems. They look primarily at what or if systems exist. They do not always understand how the systems operate and interact to control all the inputs that results in acceptable and superior products.

Agenda
Module 1: The role of the quality system & and regulatory loop
Module 2: Key to success is management involvement, organizing, and training of all functions.
Module 3: Management of Documentation and Records
Module 4: Design Control
Module 5: Facilities, Equipment & Environment
Module 6: Material –Purchasing Controls-Specification, Qualification and Control of Suppliers, and controlling incoming materials
Module 7: Technical and "Administrative" Process Controls
Module 8: Introduction to Deviations & Quality Failures (0:10)
Module 9: Validation
Module 10: Maintaining Label Control-From Design to Label Application
Module 11: Storage and Distribution & Returned and Salvaged Products
Module 12: Returned and Salvaged Products
Module 13: Laboratory Controls
Module 14: Problem Solving-Nonconforming, Investigations, and CAPA systems

Who will benefit:
  • Quality, quality control, regulatory, engineering, and manufacturing and IT staff working in the FDA regulated industry in the development and manufacture of medical products.
  • Interdepartmental functions associated with scaling up and commercializing a new medical product
  • Suppliers and software vendors, servicing the FDA regulated industry, who want to better understand the customer’s needs and requirements.
 
 
Organized by: GlobalCompliancePanel
Invited Speakers: Howard enjoys sharing his 30 years plus experience in starting up, developing, implementing, managing, and remediating pharmaceutical and medical device quality systems. He has a BS in Biology/Chemistry and Political Science as well as work toward an MBA. His ability to quickly learn the technology is demonstrated by his success in applying quality assurance principles to a wide range of pharmaceuticals and medical devices. He is a Certified Biomedical Auditor (CBA), Certified Quality Manager (CQM), and Quality Auditor (CQA). His technical education is further complemented by his Political Science degree helping him understand the regulatory process; his work toward an MBA provides business insight. He is a member of ASQ, PDA, AAMI, RAPS, and SQA. He strongly believes that Quality is very influential in shaping successful operations. He knows how to use his leadership abilities to build organizational relationships that make systems operate effectively as well as to develop and empower people.
 
Deadline for Abstracts: 2011-02-03
 
Registration:
Thursday, February 3, 2011  
10:00 AM PST | 01:00 PM EST
Live live online training only for one participant
Price: $395.00
 
 
 
Corporate Live 4 to 10 participants from a single location (For multiple locations contact Customer Care)
Price: $1,195.00
 

Recorded Access recorded version only for one participant; unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
Price: $465.00
E-mail: webinars@globalcompliancepanel.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.